文献速递消化系统肿瘤

晚期结直肠癌药物遗传学分析:DPYD变异与化疗毒性相关

Pharmacogenetic analyses of 2183 patients with advanced colorectal cancer; potential role for common dihydropyrimidine dehydrogenase variants in toxicity to chemotherapy.
PubMed 文献 · Eur J Cancer · 2018-08-13

该研究对2183例接受奥沙利铂-氟嘧啶联合或不联合西妥昔单抗治疗的晚期结直肠癌患者,分析了超过200个常见遗传变异及4个罕见DPYD变异。结果显示DNA修复基因EXO1和XRCC1变异与缓解相关,DPYD常见及罕见变异与毒性相关,但常见变异经Bonferroni校正后均不显著。

要点

  • EXO1 Asn279Ser与缓解正相关(OR 1.9),XRCC1 Arg399Gln与缓解负相关(OR 0.7)。
  • DPYD常见变异Cys29Arg和Val732Ile与毒性相关(OR 0.8和1.6)。
  • 罕见DPYD变异Asp949Val和IVS14+1G>A与多种毒性增加相关(OR均>3)。

核心结论

  • DNA修复基因可能在晚期结直肠癌药物遗传学中起重要作用。
  • 常见和罕见DPYD变异均可能与氟嘧啶类化疗毒性相关。

研究设计与样本

  • 研究纳入2183例接受奥沙利铂-氟嘧啶化疗(联合或不联合西妥昔单抗)的晚期结直肠癌患者,来自MRC COIN和COIN-B试验。
  • 分析超过200个潜在功能性常见遗传变异(位于5FU、卡培他滨、奥沙利铂及DNA修复通路基因)及4个罕见DPYD变异。
  • 主要终点为缓解、任何毒性及周围神经病变;对次要等位基因频率>20%的变异,检测OR=1.3的把握度>85%。

主要发现

  • EXO1 Asn279Ser与缓解相关(OR 1.9,95%CI 1.2-2.9,P=0.004),XRCC1 Arg399Gln与缓解相关(OR 0.7,95%CI 0.5-0.9,P=0.003)。
  • DPYD Cys29Arg与毒性相关(OR 0.8,95%CI 0.7-1.0,P=0.008),DPYD Val732Ile与毒性相关(OR 1.6,95%CI 1.1-2.1,P=0.006)。
  • 罕见DPYD变异Asp949Val与中性粒细胞减少、恶心呕吐、腹泻和感染相关;IVS14+1G>A与乏力、腹泻、口腔炎、手足综合征和感染相关;所有OR>3。
  • DCLRE1A Asp317His与周围神经病变相关(OR 1.3,95%CI 1.1-1.6,P=0.003)。
  • 经Bonferroni校正后,无常见变异关联保持显著。

临床怎么用

  • DPYD常见及罕见变异可能与氟嘧啶类化疗毒性相关,但常见变异经多重校正后不显著,临床决策需谨慎。
  • DNA修复基因变异与缓解的关联需进一步验证,暂不推荐用于常规疗效预测。

局限性

  • 常见变异关联经Bonferroni校正后均不显著。
  • 研究结果需外部验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Inherited genetic variants may influence response to, and side-effects from, chemotherapy. We sought to generate a comprehensive inherited pharmacogenetic profile for oxaliplatin and 5FU/capecitabine therapy in advanced colorectal cancer (aCRC). METHODS: We analysed more than 200 potentially functional, common, inherited variants in genes within the 5FU, capecitabine, oxaliplatin and DNA repair pathways, together with four rare dihydropyrimidine dehydrogenase (DPYD) variants, in 2183 aCRC patients treated with oxaliplatin-fluoropyrimidine chemotherapy with, or without, cetuximab (from MRC COIN and COIN-B trials). Primary end-points were response, any toxicity and peripheral neuropathy. We had >85% power to detect odds ratios (ORs) = 1.3 for variants with minor allele frequencies >20%. RESULTS: Variants in DNA repair genes (Asn279Ser in EXO1 and Arg399Gln in XRCC1) were most associated with response (OR 1.9, 95% confidence interval [CI] 1.2-2.9, P = 0.004, and OR 0.7, 95% CI 0.5-0.9, P = 0.003, respectively). Common variants in DPYD (Cys29Arg and Val732Ile) were most associated with toxicity (OR 0.8, 95% CI 0.7-1.0, P = 0.008, and OR 1.6, 95% CI 1.1-2.1, P = 0.006, respectively). Two rare DPYD variants were associated with increased toxicity (Asp949Val with neutropenia, nausea and vomiting, diarrhoea and infection; IVS14+1G>A with lethargy, diarrhoea, stomatitis, hand-foot syndrome and infection; all ORs > 3). Asp317His in DCLRE1A was most associated with peripheral neuropathy (OR 1.3, 95% CI 1.1-1.6, P = 0.003). No common variant associations remained significant after Bonferroni correction. CONCLUSIONS: DNA repair genes may play a significant role in the pharmacogenetics of aCRC. Our data suggest that both common and rare DPYD variants may be associated with toxicity to fluoropyrimidine-based chemotherapy.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Madi A, Fisher D, Maughan TS, et al. Pharmacogenetic analyses of 2183 patients with advanced colorectal cancer; potential role for common dihydropyrimidine dehydrogenase variants in toxicity to chemotherapy. Eur J Cancer. 2018. PMID: 30114658. doi:10.1016/j.ejca.2018.07.009

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。